Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration-sensitive Prostate Cancer”

154 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 154 results

Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Not applicableActive Not RecruitingNCT05901649
What this trial is testing

The Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Janssen-Cilag Ltd. 504
Testing effectiveness (Phase 2)Active Not RecruitingNCT06734130
What this trial is testing

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Not applicableUnknownNCT05161728
What this trial is testing

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Roderick van den Bergh 150
Testing effectiveness (Phase 2)Looking for participantsNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 36
Not applicableLooking for participantsNCT07146113
What this trial is testing

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Who this might be right for
Prostate Cancer
AstraZeneca 400
Large-scale testing (Phase 3)Looking for participantsNCT06177015
What this trial is testing

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Who this might be right for
Metastatic Prostate CancerIntermitent Anti-androgen Therapy
The First Affiliated Hospital with Nanjing Medical University 200
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Early research (Phase 1)Not Yet RecruitingNCT06099990
What this trial is testing

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 660
Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Not applicableStudy completedNCT05701007
What this trial is testing

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer 1,083
Post-approval studies (Phase 4)Active Not RecruitingNCT06479187
What this trial is testing

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
Brigham and Women's Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04335682
What this trial is testing

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Who this might be right for
Metastatic Prostate CancerProstate Cancer MetastaticProstate Cancer+3 more
Alliance Foundation Trials, LLC. 111
Testing effectiveness (Phase 2)Study completedNCT02059213
What this trial is testing

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 72
Early research (Phase 1)Study completedNCT04712396
What this trial is testing

Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Who this might be right for
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
AstraZeneca 11
Testing effectiveness (Phase 2)Ended earlyNCT03827473
What this trial is testing

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer+2 more
University of Utah 1
Large-scale testing (Phase 3)Looking for participantsNCT05983783
What this trial is testing

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerChemotherapy Effect
The First Affiliated Hospital with Nanjing Medical University 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07268794
What this trial is testing

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University 112
Load More Results